Hexarelin is a synthetic hexapeptide growth hormone-releasing peptide (GHRP) with the sequence His-D-2-methylTrp-Ala-Trp-D-Phe-Lys-NH2 and a molecular weight of approximately 887.0 Da, acting as a potent agonist at the ghrelin receptor (GHS-R1a) to stimulate GH release from anterior pituitary somatotrophs — with research demonstrating among the highest GH-releasing potency of the GHRP class, making it a valuable pharmacological tool for investigating maximal GHS-R1a-mediated GH secretion and downstream somatotropic axis effects in preclinical models.
Beyond its well-characterized GH secretagogue activity, Hexarelin has been studied extensively for direct cardioprotective effects through a GH-independent mechanism — with research demonstrating binding to the CD36 scavenger receptor in cardiac tissue and cardioprotective effects in ischemia-reperfusion models, myocardial infarction paradigms, and heart failure models independent of pituitary GH release, establishing it as a unique dual-mechanism research compound spanning neuroendocrine and cardiac biology.
Research has focused on Hexarelin’s dual role as a maximally-potent GHS-R1a agonist and direct cardiac receptor ligand — with comparative research designs using it alongside Ipamorelin (selective, low-potency GHRP), CJC-1295 No DAC (GHRH pathway), and IGF-1 LR3 (direct IGF-1 axis) enabling systematic dissection of GH axis pharmacology. For further reading see: Hexarelin GH secretagogue and cardioprotective research (PubMed).
Specifications:
- Purity: ≥99% (HPLC verified)
- Form: Lyophilized powder
- Storage: −20°C
For Research Use Only.
Reviews
There are no reviews yet.